Travere Therapeutics' Operating Income rose 144.40% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.1 million, marking a year-over-year increase of 74.50%. This contributed to the annual value of -$323.8 million for FY2024, which is 16.57% up from last year.
As of Q3 2025, Travere Therapeutics' Operating Income stood at $24.9 million, which was up 297.08% from -$12.7 million recorded in Q2 2025.
Travere Therapeutics' 5-year Operating Income high stood at $24.9 million for Q3 2025, and its period low was -$139.2 million during Q1 2024.
Over the past 3 years, Travere Therapeutics' median Operating Income value was -$67.7 million (recorded in 2024), while the average stood at -$67.5 million.
In the last 5 years, Travere Therapeutics' Operating Income crashed by 215.58% in 2021 and then skyrocketed by 144.40% in 2025.
Over the past 5 years, Travere Therapeutics' Operating Income (Quarterly) stood at -$84.8 million in 2021, then decreased by 2.18% to -$86.7 million in 2022, then dropped by 8.69% to -$94.2 million in 2023, then spiked by 35.55% to -$60.7 million in 2024, then soared by 144.40% to $24.9 million in 2025.
Its Operating Income was $24.9 million in Q3 2025, compared to -$12.7 million in Q2 2025 and -$42.7 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value